Using method and compositions comprising immunomodulatory compounds for treatment and management of myeloproliferative diseases

A bone marrow proliferation, immune regulation technology, applied in the prevention and/or control of myeloproliferative diseases and related syndromes, therapeutic field

Inactive Publication Date: 2007-06-20
CELGENE CORP
View PDF79 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0024] Although many of these compounds have shown promise as therapeutic agents, their mechanisms of action and effects are still being investigated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Using method and compositions comprising immunomodulatory compounds for treatment and management of myeloproliferative diseases
  • Using method and compositions comprising immunomodulatory compounds for treatment and management of myeloproliferative diseases
  • Using method and compositions comprising immunomodulatory compounds for treatment and management of myeloproliferative diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] A first embodiment of the present invention includes methods of treating and preventing MPD comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of an immunomodulatory compound or a pharmaceutically acceptable salt, solvate, hydrate, Stereoisomers, clathrates or prodrugs. This embodiment includes the treatment, prevention or management of specific MPD subtypes such as, but not limited to, polycythemia vera (PRV), essential thrombocythemia (PT), and unexplained myeloid dysplasia (AMM).

[0031] As used herein, the term "myeloproliferative disorder" or "MPD" means a disorder of hematopoietic stem cells that is characterized by one or more of the following: , elevated white blood cell count, and / or elevated platelet count) clonal expansion of pleiotropic hematopoietic progenitor cells, presence of the Philadelphia chromosome or bcr-abl gene, lacrimal dysplasia on peripheral blood smear, leukobl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods of treating, preventing and / or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and / or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Description

1. Field of invention [0001] The present invention relates to methods of treating, preventing and / or managing myeloproliferative disorders and related syndromes comprising the administration of immunomodulatory compounds alone or in combination with other treatments. 2. Background of the invention [0002] 2.1 Pathology of MPD [0003] Myeloproliferative disorders (MPDs) refer to a group of disorders characterized by clonal abnormalities of hematopoietic stem cells. See, eg, Current Medical Diagnosis & Treatment, p. 499 (37th ed., Tierney et al. eds. Appleton & Lange, 1998). As stem cells give rise to myeloblasts, erythrocytes, and platelets, qualitative and quantitative variations are seen in all of these cell lines (ibid.). [0004] MPD is further subdivided according to the predominantly proliferating myeloid cell type. Classify excess red blood cells as "polycythemia rubra vera (PRV)" or "polycythemia vera" and excess platelets as "primary (or idiopathic) thrombocytos...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/455
CPCA61K31/455A61K31/454A61K31/724A61K45/06A61P19/08A61P37/02A61P43/00A61K2300/00
Inventor 杰罗米·B·杰奥迪斯
Owner CELGENE CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap